CSIMarket
 


Protagonist Therapeutics inc   (PTGX)
Other Ticker:  
 

Protagonist Therapeutics Inc 's Quick Ratio

PTGX's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Protagonist Therapeutics Inc 's Cash & cash equivalent grew by 6.51 % in the IV Quarter 2023 sequentially, while Current Liabilities decreased, this led to improvement in Protagonist Therapeutics Inc 's Quick Ratio to 16.06, above Protagonist Therapeutics inc average Quick Ratio.

Within Major Pharmaceutical Preparations industry 7 other companies have achieved higher Quick Ratio than Protagonist Therapeutics Inc in forth quarter 2023. While Quick Ratio total ranking has improved so far during the IV Quarter 2023 to 51, from total ranking in the third quarter 2023 at 255.

Explain Quick Ratio?
How much Cash & cash equivalents PTGX´s has?
What are PTGX´s Current Liabilities?


PTGX Quick Ratio (Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Current Liabilities Change -31.77 % -24.18 % -40.25 % -46.55 % -29.16 %
Y / Y Cash & cash equivalent Change 43.93 % 19.94 % 7.37 % -24.41 % -27.39 %
Quick Ratio MRQ 16.06 11.51 13.08 9.93 7.61
PTGX's Total Ranking # 51 # 255 # 261 # 157 # 382
Seq. Current Liabilities Change -23.66 % 16.35 % 3.11 % -25.5 % -15.17 %
Seq. Cash & cash equivalent Change 6.51 % 2.35 % 35.81 % -2.78 % -11.25 %



Quick Ratio forth quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 8
Healthcare Sector # 12
Overall Market # 51


Quick Ratio Statistics
High Average Low
18.42 7.75 1.79
(Sep 30 2016)   (Sep 30 2017)




Financial Statements
Protagonist Therapeutics Inc 's Current Liabilities $ 21 Millions Visit PTGX's Balance sheet
Protagonist Therapeutics Inc 's Cash & cash equivalent $ 342 Millions Visit PTGX's Balance sheet
Source of PTGX's Sales Visit PTGX's Sales by Geography


Cumulative Protagonist Therapeutics Inc 's Quick Ratio

PTGX's Quick Ratio for the trailling 12 Months

PTGX Quick Ratio

(Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Current Liabilities TTM Growth -31.77 % -24.18 % -40.25 % -46.55 % -29.16 %
Y / Y Cash & cash equivalent TTM Growth 43.93 % 19.94 % 7.37 % -24.41 % -27.39 %
Quick Ratio TTM 12.53 10.38 9.11 7.83 7.27
Total Ranking TTM # 11 # 173 # 1942 # 3502 # 204
Seq. Current Liabilities TTM Growth -23.66 % 16.35 % 3.11 % -25.5 % -15.17 %
Seq. Cash & cash equivalent TTM Growth 6.51 % 2.35 % 35.81 % -2.78 % -11.25 %


On the trailing twelve months basis PTGX Cash & cash equivalent soared by 43.93 % in IV Quarter 2023 year on year, while Current Liabilities faded to $21 millions, this led to increase in in Protagonist Therapeutics Inc 's Quick Ratio to 12.53, above PTGX average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 2 other companies have achieved higher Quick Ratio than Protagonist Therapeutics Inc . While Quick Ratio overall ranking has improved so far to 11, from total ranking during the twelve months ending third quarter 2023 at 173.

Explain Quick Ratio?
How much Cash & cash equivalents PTGX´s has?
What are PTGX´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 3
Healthcare Sector # 5
Within the Market # 11


trailing twelve months Quick Ratio Statistics
High Average Low
12.22 6.24 3.16
(Dec 31 2023)   (Jun 30 2018)




Companies with similar Quick Ratio in the quarter ending Dec 31 2023, within Major Pharmaceutical Preparations Industry Quick RatioDec 31 2023 MRQ Cash & cash equivalentDec 31 2023 MRQ Current Liabilities
Essa Pharma inc   40.25 $ 142.120  Millions$ 3.531  Millions
Verona Pharma Plc  36.18 $ 271.772  Millions$ 7.512  Millions
Xbiotech Inc   32.79 $ 200.023  Millions$ 6.100  Millions
Vistagen Therapeutics Inc   30.39 $ 126.559  Millions$ 4.165  Millions
Morphic Holding inc   28.43 $ 704.349  Millions$ 24.776  Millions
Roivant Sciences Ltd   27.24 $ 6,670.810  Millions$ 244.899  Millions
Belite Bio Inc  24.27 $ 88.157  Millions$ 3.633  Millions
Astria Therapeutics inc   21.97 $ 246.530  Millions$ 11.221  Millions
Diamedica Therapeutics Inc   19.57 $ 52.895  Millions$ 2.703  Millions
Edgewise Therapeutics inc   18.98 $ 318.393  Millions$ 16.771  Millions
Structure Therapeutics Inc   18.89 $ 467.323  Millions$ 24.740  Millions
Sagimet Biosciences inc   16.98 $ 94.897  Millions$ 5.589  Millions
Protagonist Therapeutics inc   16.06 $ 341.617  Millions$ 21.274  Millions
Lyell Immunopharma Inc   15.82 $ 546.223  Millions$ 34.519  Millions
Agios Pharmaceuticals Inc   14.67 $ 776.928  Millions$ 52.947  Millions
Anixa Biosciences Inc   14.34 $ 23.798  Millions$ 1.660  Millions
Keros Therapeutics Inc   13.59 $ 331.147  Millions$ 24.373  Millions
Vyne Therapeutics Inc   12.38 $ 93.307  Millions$ 7.538  Millions
Rallybio Corporation  11.87 $ 109.929  Millions$ 9.263  Millions
Gh Research Plc  11.70 $ 78.420  Millions$ 6.701  Millions
Rezolute Inc   11.56 $ 92.598  Millions$ 8.008  Millions
Immuneering Corporation  11.35 $ 85.666  Millions$ 7.545  Millions
Compass Pathways Plc  11.25 $ 220.640  Millions$ 19.604  Millions
Anaptysbio Inc   10.96 $ 390.904  Millions$ 35.665  Millions
Prothena Corporation Public Limited Company  10.88 $ 618.830  Millions$ 56.891  Millions
Cassava Sciences Inc  10.86 $ 121.136  Millions$ 11.158  Millions
Cymabay Therapeutics Inc   10.70 $ 394.255  Millions$ 36.843  Millions
Spyre Therapeutics Inc   10.61 $ 339.277  Millions$ 31.978  Millions
Ovid Therapeutics Inc   10.35 $ 105.833  Millions$ 10.228  Millions
Cryoport inc   10.05 $ 458.435  Millions$ 45.610  Millions

Date modified: 2024-02-28T15:09:51+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com